Pfizer axes oral GLP-1 asset over liver injury, blowing hole in obesity plan

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for the obesity market.